← Eichor
Study identifier: NCT05945407 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer

Condition: Endometrial Neoplasms · Endometrial Neoplasm Malignant · Endometrial Neoplasm Malignant Stage I  ·  Sponsor: Peking University People's Hospital

PhaseNA
Planned participants57
Who can joinFemale, 18 Years to 45 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Jianliu Wang, Professor  ·  0086-010-88324381  ·  wangjianliu1203@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University People's HosoitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05945407